Jazz Pharmaceuticals (JAZZ) Return on Capital Employed (2011 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Return on Capital Employed of 0.4% for Q1 2026, down 603.0% year-over-year from 0.08% in Q1 2025, and up 91.45% quarter-over-quarter from 4.64% in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Return on Capital Employed (2011 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 0.4% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 603.0% year-over-year to 0.4%; the TTM figure through Mar 2026 stood at 0.4% (down 603.0% YoY), while the FY2025 annual figure was 4.48%, down 1120.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 0.4%, up from 4.64% in the prior quarter.
- The five-year high for Return on Capital Employed was 6.46% in Q4 2024, with the low at 5.57% in Q3 2025.
- The 5-year median for Return on Capital Employed is 2.0% (2023), against an average of 1.67%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed soared 660 bps in 2023, then plunged 1158 bps in 2025.
- Jazz Pharmaceuticals' Return on Capital Employed stood at 0.68% in 2022, then jumped by 975 bps to 5.93% in 2023, then gained by 9 bps to 6.46% in 2024, then plunged by 172 bps to 4.64% in 2025, then soared by 91 bps to 0.4% in 2026.
- Business Quant data shows JAZZ's Return on Capital Employed at 0.4% in Q1 2026, 4.64% in Q4 2025, and 5.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 9.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.71% |
| Mar 31, 2026 | -0.40% |
| Dec 31, 2025 | -4.64% |
| Sep 30, 2025 | -5.57% |
| Jun 30, 2025 | -3.18% |
| Mar 31, 2025 | 5.63% |
| Dec 31, 2024 | 6.46% |
| Sep 30, 2024 | 6.02% |
| Jun 30, 2024 | 5.73% |
| Mar 31, 2024 | 5.29% |
| Dec 31, 2023 | 5.93% |
| Sep 30, 2023 | 2.00% |
| Jun 30, 2023 | 0.44% |
| Mar 31, 2023 | -0.27% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | 2.48% |
| Jun 30, 2022 | 2.33% |
| Mar 31, 2022 | 0.85% |
| Dec 31, 2021 | 1.47% |
| Sep 30, 2021 | 2.43% |